Autopsy report · NCT00824538
Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow
Cause of deathSafety, also slow enrollment
“Closed prematurely due to emerging data on toxicity and competing trials.”
Life of this trial
- Ran for about 4 years 10 months before it stopped.
- 13 participants enrolled.
- Results were posted on the registry 5 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- University of California, San Francisco
- Sponsor type
- University, hospital or other
- Conditions
- Breast Cancer
- Interventions
- sunitinib malate; flow cytometry; immunohistochemistry staining method; laboratory biomarker analysis
- Participants
- 13
Trials that died the same way
- Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib
“Enrollment held for toxicity evaluation; then closed due to competing trial” - Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
“the study was closed early due to competing trials” - Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
“Due to study design (and toxicity), this trial closed to accrual prior to opening the phase II portion.” - A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors
“Study was prematurely discontinued due to unacceptable toxicity.” - Subcutaneous Recombinant Human Hyaluronidase: Workflow Analysis and Emergency Department Design
“This study was closed before accrual due to FDA recall of Medication”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.